Morgan Stanley Reiterates Underweight Rating on GlaxoSmithKline (GSK:LN) (GSK): "risk/reward skewed to downside"
Tweet Send to a Friend
Morgan Stanley analyst Sarita Kapila reiterated an Underweight rating and GBp1,700.00 price target on GlaxoSmithKline ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
